Kalydeco
Vertex scores EU approval for cystic fibrosis drug Kalydeco in R117H+ children and adolescents
June 10, 2020Research and Development, Sales and Marketing Kalydeco, Vertex, cystic fibrosis, ivacaftor, pharma
Vertex has revealed that it has secured a new approval from the European Commission for its therapy Kalydeco (ivacaftor) in …
Vertex’s Kalydeco seizes EU CHMP recommendation for Kalydeco in R117H+ cystic fibrosis
May 1, 2020Medical Communications, Sales and Marketing Europe, Kalydeco, Vertex, cystic fibrosis
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has given its recommendation for the approval …
Vertex’s cystic fibrosis portfolio to be made available across Northern Ireland and Wales
November 13, 2019Research and Development, Sales and Marketing Kalydeco, NHS, Orkambi, Symkevi, Vertex, pharma
After drawn out negotiations and much discontent among cystic fibrosis (CF) patients and their advocates, Vertex has announced that a …
Scottish Medicines Consortium does not back Vertex’ cystic fibrosis drugs Orkambi, Kalydeco
May 10, 2016Manufacturing and Production, Research and Development Kalydeco, Orkambi, SMC, Vertex Pharma, cystic fibrosis, regulation
The Scottish Medicines Consortium did not back two cystic fibrosis therapies from Vertex Pharmaceutical (Nasdaq: VRTX). SMC did not recommend …
Vertex admits blunder over drug data
May 31, 2012Sales and Marketing Kalydeco, Kalydeco., Vertex, cystic fibrosis
Vertex has been embarrassed after it released claims for its pipeline drug VX-809 which turned out to be incorrect. The …
Landmark CF treatment set for European approval
May 30, 2012Sales and Marketing CHMP, Europe, Kalydeco, Vertex, cystic fibrosis
A European committee is recommending the approval of Vertex’s first-in-class treatment for cystic fibrosis. Kalydeco (ivacaftor) is a landmark in …
Groundbreaking CF drug recommended in Europe
May 25, 2012Sales and Marketing CHMP, EMA, Kalydeco, Vertex, cystic fibrosis
The first-in-class treatment for cystic fibrosis Kalydeco has been recommended by the EMA’s medicines committee. Kalydeco (ivacaftor) promises to be …
